Comparison Between the Prognostic Value of Left Ventricular Function and Myocardial Perfusion Reserve in Patients with Ischemic Heart Disease


1Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands; 2Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands; 3Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; 4Department of Cardiology, AZ Maria Middelares, Ghent, Belgium; 5Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands; and 6Department of Surgery, Division of Vascular Surgery, University Medical Center Groningen, Groningen, The Netherlands

The purpose of this study was to compare the prognostic value of left ventricular ejection fraction (LVEF) and myocardial perfusion reserve (MPR) assessed with PET in patients with ischemic heart disease (IHD). Myocardial perfusion is the main determinant of left ventricular function in patients with IHD. The prognostic value of LVEF has been widely established. In addition, MPR determines survival in patients with hypertrophic and dilated cardiomyopathies. In the present study, we evaluated whether MPR also determines survival in patients with IHD. Methods: Between 1995 and 2003, 480 consecutive patients with chronic IHD underwent dipyridamole stress and rest 13N-ammonia PET to determine MPR. Additionally, 18F-FDG PET was performed for viability (mismatching defects), infarction (matching defects), and left ventricular function assessment. Patients were followed for all causes of mortality and major cardiovascular events. Results: In 463 of the 480 patients, valid MPR could be measured (368 men; mean age, 66 ± 11 y; LVEF, 35% ± 15%). One hundred nineteen patients underwent a PET-driven revascularization (67 through percutaneous coronary intervention and 52 through coronary artery bypass grafting). The remaining 344 patients were the subject of this study. The overall MPR was 1.71 ± 0.50 (intertertile boundaries, 1.49 and 1.84). After adjustment for age and sex, MPR was associated with a hazard ratio for cardiac death of 4.11 (95% confidence interval, 2.98–5.67) per SD decrease, whereas the risk for LVEF was 2.76 (2.00–3.82) per SD decrease. Conclusion: Patients with IHD with a low MPR are at high risk of cardiac death. MPR is a more sensitive predictor for cardiac death than is LVEF.

Key Words: positron emission tomography; myocardial blood flow quantification; coronary artery disease; endothelial function; prognosis; LV function

DOI: 10.2967/jnumed.108.054395

Ischemic heart disease (IHD) is a progressive disease eventually leading to loss of ventricular function and cardiac death (1). Patients with one or more previous myocardial infarctions and one or more coronary interventions often pose a difficult therapeutic dilemma. The question arises of whether to treat only medically or to aim also (again) at an intervention. Careful analysis of myocardial perfusion in combination with viability and function can guide patient-tailored therapeutic strategies (2). PET using 18F-FDG combined with the flow tracer 13N-ammonia is an accurate, noninvasive diagnostic technique to assess myocardial viability and ischemia in patients with chronic IHD (3,4) It has been shown that not only the extent of PET-based viable myocardium but also the extent of infarcted myocardium is an important predictor of left ventricular function recovery after revascularization (5). Most PET studies for analysis of patient survival after treatment have been based on semiquantitative scoring of myocardial perfusion and 18F-FDG distribution. Dynamic imaging with PET allows the quantitative assessment of myocardial tracer kinetics and, hence, the measurement of physiologic processes such as myocardial blood flow, using the model of Hutchins et al. (6). In addition, and in contrast to SPECT, PET enables absolute measurements of myocardial blood flow, permitting the assessment of coronary perfusion reserve.

In previous studies, the prognostic value of myocardial perfusion reserve (MPR) was established in patients without coronary artery disease (7), in patients with hypertrophic
cardiomyopathy (8,9), and in patients with idiopathic left ventricular dysfunction (10,11). Whether this prognostic value holds true for patients with epicardial IHD is unknown. Therefore, we investigated whether, in comparison with left ventricular ejection fraction (LVEF), MPR assessed with PET using absolute myocardial blood flow quantification and perfusion reserve can predict survival in a large group of patients with IHD.

MATERIALS AND METHODS

Patients and Study Design

This study prospectively included, with retrospective analysis, 480 subjects with advanced IHD who underwent rest 13N-ammonia, dipyridamole stress 13N-ammonia, and gated 18F-FDG PET, between 1995 and 2003 at the PET center of the University Medical Center Groningen, for evaluation of stress-induced ischemia and myocardial viability. Patient data were collected from the hospital information system (Table 1). PET-driven intervention was defined as any cardiac (surgical or percutaneous) procedure performed within the first 6 mo after the PET study date. If no intervention was performed, the patients were considered to be only medically treated.

Endpoints

All causes of mortality were assessed. Cardiac death was defined as sudden death, death after the onset of symptoms suggestive of cardiac ischemia, or death due to heart failure. Cardiac events included cardiac death, myocardial infarction, and non-PET-driven revascularization. Myocardial infarction was defined as an increase in cardiac enzymes (>2x the upper limit of normal), new pathologic Q waves on the electrocardiogram, or both. A major adverse cardiac event was defined as cardiac death, myocardial infarction, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or hospitalization for an acute coronary syndrome or heart failure.

PET

The patients underwent dynamic rest 13N-ammonia, dipyridamole stress 13N-ammonia, and gated 18F-FDG PET using a 1-d protocol, as described previously (12). Briefly, PET studies were performed after the patients had discontinued vasoactive medica-

---

**Table 1. Patient Characteristics for Each Tertile of MPR**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>MPR, first tertile (&lt;1.49) (n = 114)</th>
<th>MPR, second tertile (1.49–1.84) (n = 116)</th>
<th>MPR, third tertile (&gt;1.84) (n = 114)</th>
<th>Total (n = 344)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>69 ± 11</td>
<td>68 ± 10</td>
<td>62 ± 11</td>
<td>66 ± 11</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sex (F/M) (n)</td>
<td>22/92</td>
<td>26/90</td>
<td>25/89</td>
<td>73/271</td>
<td>0.628</td>
</tr>
<tr>
<td>Hypercholesterolemia (%)</td>
<td>54</td>
<td>53</td>
<td>64</td>
<td>57</td>
<td>0.141</td>
</tr>
<tr>
<td>Smoking (%)</td>
<td>31</td>
<td>28</td>
<td>38</td>
<td>33</td>
<td>0.323</td>
</tr>
<tr>
<td>Diabetes mellitus (%)</td>
<td>12</td>
<td>17</td>
<td>10</td>
<td>13</td>
<td>0.539</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>28</td>
<td>29</td>
<td>29</td>
<td>29</td>
<td>0.884</td>
</tr>
<tr>
<td>Family history (%)</td>
<td>32</td>
<td>40</td>
<td>54</td>
<td>42</td>
<td>0.001</td>
</tr>
<tr>
<td>Previous myocardial infarction (%)</td>
<td>82</td>
<td>71</td>
<td>61</td>
<td>71</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Previous CAGB (%)</td>
<td>29</td>
<td>31</td>
<td>26</td>
<td>29</td>
<td>0.661</td>
</tr>
<tr>
<td>Previous PCI (%)</td>
<td>44</td>
<td>42</td>
<td>48</td>
<td>45</td>
<td>0.506</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>30 ± 14</td>
<td>37 ± 13</td>
<td>41 ± 17</td>
<td>36 ± 15</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Typical anginal complaints (%)</td>
<td>77</td>
<td>85</td>
<td>81</td>
<td>81</td>
<td>0.747</td>
</tr>
<tr>
<td>Left ventricular end-diastolic volume (mL)</td>
<td>172 ± 91</td>
<td>124 ± 62</td>
<td>124 ± 81</td>
<td>140 ± 82</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Coumarin (%)</td>
<td>44</td>
<td>29</td>
<td>25</td>
<td>33</td>
<td>0.003</td>
</tr>
<tr>
<td>Statin (%)</td>
<td>52</td>
<td>48</td>
<td>61</td>
<td>54</td>
<td>0.185</td>
</tr>
<tr>
<td>Diuretic (%)</td>
<td>47</td>
<td>31</td>
<td>24</td>
<td>34</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Digoxin (%)</td>
<td>22</td>
<td>11</td>
<td>8</td>
<td>14</td>
<td>0.002</td>
</tr>
<tr>
<td>β-blocker (%)</td>
<td>64</td>
<td>70</td>
<td>60</td>
<td>65</td>
<td>0.489</td>
</tr>
<tr>
<td>Angiotensin-converting enzyme-inhibitor/ARB (%)</td>
<td>58</td>
<td>40</td>
<td>42</td>
<td>47</td>
<td>0.017</td>
</tr>
<tr>
<td>Matching defect (% left ventricle)</td>
<td>30 ± 15</td>
<td>27 ± 15</td>
<td>25 ± 17</td>
<td>27 ± 16</td>
<td>0.012</td>
</tr>
<tr>
<td>Location of matching defects:</td>
<td>29/33/44</td>
<td>34/30/55</td>
<td>32/18/51</td>
<td>31/27/50</td>
<td>0.669/0.007/0.290</td>
</tr>
<tr>
<td>Mismatching defect (% left ventricle)</td>
<td>11 ± 10</td>
<td>8 ± 10</td>
<td>7 ± 9</td>
<td>9 ± 10</td>
<td>0.011</td>
</tr>
<tr>
<td>Location of mismatching defects:</td>
<td>27/37/33</td>
<td>26/24/28</td>
<td>14/33/22</td>
<td>22/31/28</td>
<td>0.017/0.393/0.055</td>
</tr>
<tr>
<td>Normal area of left ventricle (%)</td>
<td>59 ± 19</td>
<td>65 ± 19</td>
<td>68 ± 21</td>
<td>64 ± 20</td>
<td>0.001</td>
</tr>
<tr>
<td>Myocardial perfusion at rest (mL/min/100 g)</td>
<td>86 ± 23</td>
<td>85 ± 22</td>
<td>80 ± 21</td>
<td>87 ± 23</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Myocardial perfusion during stress (mL/min/100 g)</td>
<td>117 ± 34</td>
<td>139 ± 36</td>
<td>177 ± 45</td>
<td>145 ± 46</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**Table 1.** Patient Characteristics for Each Tertile of MPR

- **MPR** = myocardial perfusion reserve
- **LAD** = left anterior descending coronary artery
- **LCX** = left circumflex coronary artery
- **RCA** = right coronary artery

Categoric variables are shown as percentage or as number; continuous variables as mean ± SD.
tion for 5 plasma half-lives and had refrained from caffeinated beverages for a minimum of 12 h. Imaging was performed with the patient supine and used an ECAT 951 positron camera (Siemens CTI). Thirty-one planes were measured simultaneously over a length of 10.8 cm. The measured resolution of the system was 6 mm in full width at half maximum. Data were automatically corrected for accidental coincidence and dead time. Patients were positioned with the help of a rectilinear scan. Photon attenuation was measured using a retractable external ring source filled with 68Ge/68Ga. Perfusion imaging was performed after dipyridamole had been infused (0.56 mg/kg in 4 min). Imaging was started by injecting 400 MBq of 13N-ammonia 6 min after the start of dipyridamole infusion and continued for 15 min.

To stimulate 18F-FDG uptake, patients were given 75 g of glucose orally just before scanning or were given 500 mg of acipimox (Nedios; Byk Pharmaceuticals) orally 90 min before scanning to lower circulating free fatty acids (13). To prevent side effects of acipimox (e.g., skin rash), 250 mg of aspirin were administered orally 5 min before acipimox. In diabetic patients, 18F-FDG imaging was done with hyperinsulinemic euglycemic glucose clamping (14). After the 13N-ammonia data had been acquired, 200 MBq of 18F-FDG were injected intravenously, followed by a PET dynamic acquisition. The total 18F-FDG PET acquisition time was 40 min, with the last 20 min acquired in gated mode with 16 frames per cardiac cycle. The length of each gate was based on the current R-R interval. The R-R interval was allowed to vary by ±10%. Data were corrected for attenuation using the transmission scan and were reconstructed using filtered backprojection (Hann filter, 0.5 pixels/cycle).

Kinetic Models and Data Analysis
From the PET data, dynamic parametric polar maps were constructed (12). PET perfusion data at rest were corrected for rate-pressure product. Myocardial blood flow data were corrected for partial-volume effect and spillover and quantified by the model of Hutchins et al. (6). Briefly, myocardial and blood time–activity curves derived from regions of interest over the heart and ventricular chamber are fitted using a 3-compartment model for 13N-ammonia, yielding rate constants for tracer uptake and retention. Perfusion flow reserve (dipyridamole-to-rest ratio) was calculated by dividing the dipyridamole 13N-ammonia stress study by the 13N-ammonia rest study.

Data analysis of 18F-FDG was performed with PATLAK analysis (15). Mismatch was quantified by first normalizing the 18F-FDG uptake polar map and the dipyridamole blood flow polar map to their means. Then, a difference polar map was created by subtracting the normalized dipyridamole blood flow polar map from the normalized 18F-FDG uptake polar map. Mismatch was calculated as the percentage myocardium above the 95% confidence interval of the normal database, and results were expressed as percentage of the total myocardium. Similarly, matching areas were quantified by constructing a product polar map; the normalized dipyridamole blood flow polar map was multiplied by the normalized 18F-FDG uptake polar map. Match was defined as the percentage myocardium below the 95% confidence interval. The extent of mismatching areas (viable myocardium) and matching areas (nonviable myocardium) was calculated from these data as previously described (12).

The last frames (20-min acquisition time) of the dynamic gated 18F-FDG PET studies were summed and transformed into static studies and used for further data analysis with the help of the quantitative gated SPECT program (15). Based on the gated 18F-FDG images, left ventricular end-systolic and end-diastolic volumes, as well as LVEF, were computed.

Statistical Analysis
Descriptive results are expressed as mean ± SD. Categoric measures are presented as frequencies with percentages. Crude data were compared across tertiles of MPR, defined as perfusion during dipyridamole divided by resting perfusion, with the x2 test for trend (dichotomous variables) and generalized linear models (continuous variables). The significance of MPR, controlled for important risk modifiers as presented in Table 1 (P < 0.20), was examined with multivariable Cox proportional hazards regression analyses by using fractional polynomials (16). Results are summarized by hazard (risk) ratios with confidence intervals based on robust SE estimates. To assess the prognostic value of LVEF and MPR adjusted for age and sex, Harrell’s C-statistic was computed (comparable to the area under the receiver-operating-characteristic curve). Model fit was assessed with Bayesian information criterion statistics, which are goodness-of-fit measures adjusted by degrees of freedom and sample size. Smaller Bayesian information criterion values indicate that the model fits better. A difference of 10 points or more between a given model and the other model is strong evidence for a significantly better goodness of fit. The significance level was set at 0.05. Observations with missing values for contributing variables in the multivariate model were excluded. The statistical analysis was performed with SPSS (SPSS Inc.), version 9.1, and STATA statistical software, release 10.0 (StataCorp LP).

RESULTS

Patient Characteristics
Between 1995 and 2003, 480 patients underwent a 13N-ammonia rest, a dipyridamole stress, and a gated 18F-FDG PET scan. In 17 patients, gating was not possible because of heart rate irregularities occurring during the scan. In 463 patients, valid MPR could be measured. One hundred nineteen patients (368 men; mean age, 66 ± 11 y; LVEF, 35% ± 15%) underwent a PET-driven revascularization (67 through PCI and 52 through CABG). Patients with a PET-driven intervention were comparable to the study group with respect to age (66 ± 11 y vs. 68 ± 10 y), sex (24% female vs. 18% female), risk factors, previous myocardial infarction (71% vs. 78%), and previous PCIs (45% vs. 36%) but had significantly more previous CABGs (28% vs. 15%, P = 0.028) and a higher LVEF (36 ± 16 vs. 32 ± 14, P = 0.007). The remaining 344 patients were the subject of this study. The baseline characteristics of these 344 patients are shown in Table 1: 14% of the patients were in NYHA class I, 49% in class II, 31% in class III, and 5% in class IV. Overall, the MPR was 1.71 ± 0.50 (intertertile boundaries, 1.49 and 1.84). Areas of mismatch were found in 91 patients (27%), areas of matching defects in 267 (78%), both mismatching and matching defects in 80 (23%), and no defects at all in 66 (19%). Mean percentage match in the study group was 27% ± 16%, mean percentage mismatch was 9% ± 10%, and mean LVEF was 36% ± 15%. Coronary artery disease was present in the left anterior descending artery in 66% of
patients, in the right coronary artery in 43%, and in the circumflex coronary artery in 30%.

**Outcome Event**

The median follow-up among survivors was 85 mo (range, 1–138 mo). Among the 344 patients in this study, there were a total of 85 deaths (25%), of which 60 (17%) were cardiac deaths. Twenty-five patients (7%) experienced a nonfatal myocardial infarction. A total of 71 patients (21%) underwent a PCI and 27 a CABG (8%) during follow-up.

**Hazard Ratio of MPR**

Table 2 summarizes the results of the Cox regression analysis for cardiac death. In the univariate analysis, the parameters significantly associated with cardiac death were MPR; family history; previous myocardial infarction; LVEF; left ventricular end-diastolic volume; the use of aspirin, diuretics, or digoxin; and matching. After controlling for age and sex, the following parameters were associated with cardiac death: MPR, family history, previous myocardial infarction, LVEF, left ventricular end-diastolic volume, aspirin, diuretics, and digoxin. MPR was associated with a hazard ratio for cardiac death of 4.11 (95% confidence interval, 2.98–5.67) per SD decrease, whereas the risk for LVEF was 2.76 (2.00–3.82) per SD decrease. Interestingly, the prognostic value of MPR was independent of the extent of matching and mismatching defects. Survival data for each MPR tertile are shown in Figure 1. The hazard function of MPR, when compared with LVEF, was steeper in a prognostic model adjusted for age and sex, resulting in improved C-statistics and Bayesian information criterion statistics (0.83, 605 vs. 0.77, 620) (Fig. 2). Finally, in a secondary mutually adjusted multivariate analysis of MPR, family history, previous myocardial infarction; LVEF; left ventricular end-diastolic volume; the use of aspirin, diuretics, or digoxin; and percentage matching defects, the parameters that remained statistically significant in the model were MPR, LVEF, and the use of diuretics (hazard ratios of 4.08 [2.50–6.65, P < 0.001], 1.91 [1.10–3.31, P = 0.021], and 2.19 [1.07–4.97, P = 0.033], respectively).

**Hazard Ratio for Major Adverse Cardiac Event**

After univariate analysis of baseline demographics (including PET parameters) MPR had a hazard ratio of 1.60 (1.31–1.94, P < 0.001) for major adverse cardiac events. Finally, in a secondary mutually adjusted multivariate analysis, MPR remained statistically significant in the model (hazard ratio, 1.44 [1.14–1.84, P = 0.003]).

Interestingly, the prognostic value of MPR for cardiac death and major adverse cardiac events was independent of whether patients received a PET-driven medical strategy or a revascularization strategy and of the extent of matching or mismatching defects.

**DISCUSSION**

It has been shown that MPR is of prognostic value in patients without coronary artery disease (7) and in patients with hypertrophic or idiopathic cardiomyopathy (8–10). The present study shows comparable results in patients with IHD. Interestingly, these findings were independent of the extent of myocardial ischemia or infarction and superior to the prognostic value of LVEF. Further, a small decrease in MPR was associated with a large increment in mortality rate and showed an improved fit when compared with LVEF.

Although the prognostic value of MPR in subgroups of patients without obstructive coronary artery disease has been established, the prognostic value of PET in patients with obstructive coronary artery disease has been evaluated only with respect to areas of matching or mismatching defects (16). In previous studies, an association between the presence or extent of ischemic myocardial area and survival has been described (16–18). In 2 of these studies, the presence of mismatching defects (without absolute quantification) has been described in relation to prognosis (17,18). In contrast to the previous studies, we did not find an association between the presence or extent of mismatching defects and progno-

---

**TABLE 2. Univariate and Multivariate Cox Proportional Hazard Regression Analysis of Cardiac Death According to MPR**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate analysis</th>
<th>Age- and sex-adjusted analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hazard ratio</td>
<td>P</td>
</tr>
<tr>
<td>MPR (per SD)</td>
<td>4.18 (3.05–5.74)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Family history (yes)</td>
<td>0.56 (0.32–0.98)</td>
<td>0.043</td>
</tr>
<tr>
<td>Previous myocardial infarction (yes)</td>
<td>6.06 (2.20–16.71)</td>
<td>0.001</td>
</tr>
<tr>
<td>LVEF (per SD)</td>
<td>2.79 (2.02–3.85)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LVEDV (per 10 mL)</td>
<td>1.05 (1.03–1.08)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Aspirin (yes)</td>
<td>0.41 (0.24–0.67)</td>
<td>0.001</td>
</tr>
<tr>
<td>Diuretics (yes)</td>
<td>5.58 (3.17–9.81)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Digoxin (yes)</td>
<td>4.97 (2.94–8.39)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Matching (per 10%)</td>
<td>1.40 (1.20–1.64)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mismatching (per 10%)</td>
<td>1.20 (0.95–1.51)</td>
<td>0.134</td>
</tr>
</tbody>
</table>

CI = confidence interval; LVEDV = left ventricular end-diastolic volume.
Data in parentheses are 95% confidence intervals.
sis. The percentage of patients with a previous myocardial infarction (52%–87%) was comparable to that in our study group (73%). An explanation may be that in our patient group a larger proportion of patients had undergone a previous coronary intervention: 26% CABG and 43% PCI in our group, versus 6%–10% and 8%–9%, respectively, in the study of Desideri et al. (16) or even as low as 3% in the study of Wiggers et al. (18). The higher percentage of patients with a previous revascularization may have resulted in much smaller ischemic areas (10%–10%) in our study than in the previous study by Desideri et al. (36%–58%). Previous SPECT perfusion imaging studies are also in line with our MPR data: increasing perfusion abnormalities were associated with worsening prognosis (19). However, SPECT is not able to quantify absolute perfusion and may underdiagnose ischemia in patients with severe 3-vessel or left main coronary disease.

Our group is comparable to a previously studied group of ischemic heart failure patients with respect to the high rate of prior interventions (20). In that study, patients with ejection fractions of 23% ± 7% were evaluated. It appeared that in approximately 12% of these patients, viable myocardial segments (ischemia or hibernation) were present. These patients underwent a revascularization procedure if possible. Interestingly, in the lowest-tertile MPR group of our study, survival rates were comparable to those of the intervention group in the previous study, despite the fact that patients in our group had higher LVEFs. In contrast, patients in the higher MPR tertiles had better survival rates. Our study group consisted of a mixed population with regard to LVEF and was comparable to patients seen in clinical practice.

We did not analyze regional perfusion defects, but the fact that global perfusion reserve has such an impact on prognosis may relate to vascular dysfunction that has extended beyond the areas of stenotic coronary arteries. MPR depends mainly on the dilatory capacity of the prearteriolar sphincters in the microvasculature. Microvascular function is determined by metabolic need, structural changes, neurohumoral factors, autonomic innervation, extravascular resistance, and endothelial function. Among these factors, the endothelial component has been investigated the most extensively. Microvascular dysfunction can be found in patients without myocardial or obstructive coronary artery disease and is most often related to conventional risk factors such as smoking (21), hyperlipidemia (22,23), and diabetes (23). In addition, microvascular dysfunction can be the cause of angina pectoris in the absence of epicardial coronary disease, or the so-called syndrome-X (24). Myocardial perfusion abnormalities may influence myocardial contractility, but left ventricular dysfunction can also be mirrored by myocardial perfusion abnormalities (25).

In dilated cardiomyopathy, we have previously shown that despite the absence of IHD, regions with a lower MPR are present (11). The present study further expands these perfusion reserve data to patients with coronary artery disease. MPR can be considered a reflection of global ischemia and...
hence of the severity of coronary artery disease and left ventricular dysfunction. On the one hand, ischemia may lead to left ventricular dysfunction, but on the other hand, left ventricular dysfunction may cause abnormalities in the microvasculature (25).

Our study had some limitations. Because of the long follow-up period, a large proportion of patients underwent PET in the early 1990s. As a consequence, many patients with heart failure were still on digoxin therapy. However, the results did not differ between these patients and patients on angiotensin-converting-enzyme inhibitors. The metabolic state of the patients was not assessed at the moment of PET; however, neither fasting glucose levels nor diabetes mellitus influenced our multivariate model. The implication is that MPR is a robust determinant of prognosis, independent of the metabolic state of the patients. Furthermore, all scans were executed under glucose clamping.

This study did not evaluate regional MPR. Although MPR in this patient group can be expected to show regional differences, global MPR was found to be an important prognostic indicator. This finding may reflect global and not just regional coronary vascular failure. In comparison, dilated cardiomyopathy patients with a left bundle branch block have a lower global perfusion than do patients with no left bundle branch block, despite a heterogeneous perfusion pattern (26).

Finally, one could question what the clinical significance of MPR measurements in these patients is. Most of these patients were not amenable to coronary intervention. We believe that this may be quite relevant because the low MPR may argue in favor of a coronary intervention and of optimally treating patients with a tailored approach to improve endothelial and vascular function.

CONCLUSION

MPR assessed with PET is an important predictor of cardiac death in patients with IHD not amenable to surgical or percutaneous revascularization. Therefore, therapeutic strategies to improve MPR are of the highest importance always, not just when symptoms are worsening.

REFERENCES

17. Sorrentino AR, Acampa W, Pettetta M, Mainolfi C, Salvatore M, Cuocolo A. Comparison of the prognostic value of SPECt after nitrate administration and metabolic imaging by PET in patients with ischemic left ventricular dysfunc-
Comparison Between the Prognostic Value of Left Ventricular Function and Myocardial Perfusion Reserve in Patients with Ischemic Heart Disease


JNM
Published online: January 21, 2009.
Doi: 10.2967/jnumed.108.054395

This article and updated information are available at:
http://jnm.snmjournals.org/content/early/2009/01/21/jnumed.108.054395.citation

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml

JNM ahead of print articles have been peer reviewed and accepted for publication in JNM. They have not been copyedited, nor have they appeared in a print or online issue of the journal. Once the accepted manuscripts appear in the JNM ahead of print area, they will be prepared for print and online publication, which includes copyediting, typesetting, proofreading, and author review. This process may lead to differences between the accepted version of the manuscript and the final, published version.